Chart Review in Oncology: Surfacing Biomarkers and Inferring Eligibility from the Patient Record.
Four case studies on how Areti's PRIME engine reads pathology, surfaces molecular biomarkers, and infers ECOG and TNM from unstructured notes — with clinician verification on every inference.
- ✓The PRIME engine architecture — how it ingests notes, labs, and pathology reports, then maps to inclusion/exclusion criteria
- ✓Biomarker-driven recruitment: APOL1 CKD (Elixia) — 8× site baseline, volume-driven outreach pause
- ✓Note-level interpretation: Early Alzheimer's (Gadolin) — 55% screen-fail vs. >95% baseline
- ✓Active oncology program: DLBCL (Genentech STARGLO) — real-time immunophenotype and progression tracking
- ✓Inference framework: how PRIME reads "mostly in bed" and returns ECOG 3 — with TNM, RECIST, and pathology examples
Four case studies. One engine: PRIME.
Three completed enrollments and one active oncology program — selected to demonstrate the precise capability oncology recruitment depends on: reading the chart, surfacing medical events, and inferring eligibility that keyword search misses.
APOL1-Mediated CKD (Elixia)
A genotype-defined enrollment problem solved by record-level biomarker targeting. Structurally identical to a BRAF V600E or KRAS G12C stratified oncology trial.
Early Alzheimer's Disease (Gadolin Research)
A high-screen-fail study rescued by interpreting unstructured notes and lab narratives — the same problem oncology faces with pathology typing, ECOG, RECIST, and staging.
Challenging Lymphoma — DLBCL (Genentech STARGLO)
Real-time immunophenotype and biomarker monitoring to capture patients at the right line of therapy. Continuous re-reading of the record so the AI Coordinator reaches the patient inside the trial-eligible window.
Inferring Disease Severity & Stage from Notes
How PRIME reads "mostly in bed" and returns ECOG 3 — with the same engine surfacing TNM stage, pathology subtype, and biomarker status, and a clinician-verifiable rationale on every call.
Precise Record Retrieval, Ingestion & Matching Engine.
PRIME ingests the full longitudinal record — medical history, diagnosis, medications, procedures, labs — plus typed, dictated, and scanned narrative notes. An advanced AI layer with a clinical intelligence library surfaces biomarkers, infers disease severity and stage, and matches patients against protocol inclusion/exclusion criteria. Every inference carries a rationale verified by clinical staff, with >90% alignment between PRIME and reviewing nurses.
Want to run PRIME against two or three live oncology protocols?
A 30-minute working session is the fastest way to see biomarker surfacing, performance-status inference, and real-time progression tracking combine on a real indication.